Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 8;106(7):dju127.
doi: 10.1093/jnci/dju127. Print 2014 Jul.

Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials

Bhishamjit S Chera  1 , Avraham Eisbruch  2 , Barbara A Murphy  2 , John A Ridge  2 , Patrick Gavin  2 , Bryce B Reeve  2 , Deborah Watkins Bruner  2 , Benjamin Movsas  2
Affiliations
Review

Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials

Bhishamjit S Chera et al. J Natl Cancer Inst. .

Abstract

We identified a standard core set of patient-reported symptoms and health-related quality-of-life (HRQOL) domains to be assessed in head and neck (H&N) cancer clinical trials. The core symptom and HRQOL domain scores were used to guide recommendations by a working group of experts as part of a National Cancer Institute Symptom Management and HRQOL Clinical Trials Planning Meeting. A PubMed search was conducted using the search terms of "health-related quality of life" and "head & neck cancer," limited to publications from January 1, 2000, to December 31, 2010. Fifty-four articles were used to guide the choice of recommendations. Twenty-nine symptoms and nine domains were identified, from which 12 H&N-specific core symptoms and HRQOL domains were recommended: swallowing, oral pain, skin changes, dry mouth, dental health, opening mouth/trismus, taste, excess/thick mucous/saliva, shoulder disability/motion, voice/hoarseness, social domain, and functional domain. This core set of 12 H&N-specific, patient-reported symptoms and HRQOL domains should be assessed in future H&N cancer clinical trials.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of the selection process of articles for the literature review. Fifty-four articles were selected for evaluation and review.
See this image and copyright information in PMC

Comment in

References

    1. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26(21):3582–3589 - PMC - PubMed
    1. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705–1715 - PubMed
    1. Reeve B. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst. 2014;XX(XX):XXX–XXX. - PMC - PubMed
    1. PubMed. http://www.ncbi.nlm.nih.gov/pubmed Accessed April 28, 2014
    1. Trotti A, Pajak TF, Gwede CK, et al. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007;8(7):613–624 - PubMed

Publication types

MeSH terms